Salarius extends cash runway into H1 2025; CEO Arthur transitions to part-time consultant

Decoy Therapeutics Inc.

CEO David Arthur ends full-time employment; becomes part-time consultant effective Feb 20, 2024, at $10,417/month.
Cash runway expected to extend into first half of 2025 due to cost-saving measures including reduced director pay and operating expenses.
Ongoing strategic review with Canaccord Genuity to maximize shareholder value; clinical trials in hematologic cancers and Ewing sarcoma continue.
Clinical data: 50% ORR in hematologic cancers (MDACC trial) and 60% ORR in first-relapse Ewing sarcoma patients with seclidemstat combinations.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

David J. Arthur

President and Chief Executive Officer

DCOY · Decoy Therapeutics Inc.

Effective: 2024-02-20
Filed: February 23, 2024, 6:59 PM ET

On February 20, 2024 (the “Separation Date”), Salarius Pharmaceuticals, Inc. (the “Company”) entered into a separation and release agreement (the “Separation Agreement”) with David J. Arthur, the Company’s President and Chief Executive Officer, which provides for Mr. Arthur’s separation of employment, effective as of the Separation Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David J. Arthur changed role as President and Chief Executive Officer at Decoy Therapeutics Inc..

Action: transitioned to part-time consultant
Role: President and Chief Executive Officer

Exact text from the filing

On February 20, 2024 (the “Separation Date”), Salarius Pharmaceuticals, Inc. (the “Company”) entered into a separation and release agreement (the “Separation Agreement”) with David J. Arthur, the Company’s President and Chief Executive Officer, which provides for Mr. Arthur’s separation of employment, effective as of the Separation Date.

View on SEC.gov

Decoy Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001615219-24-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.